Literature DB >> 26768556

Trial design for evaluating novel treatments during an outbreak of an infectious disease.

John Whitehead1, Piero Olliaro2, Trudie Lang3, Peter Horby3.   

Abstract

Tragically, the outbreak of Ebola that started in West Africa in 2014 has been far more extensive and damaging than any previous outbreaks. The duration of the outbreak has, for the first time, allowed the clinical evaluation of Ebola treatments. This article discusses the designs used for two such clinical trials which have recruited patients in Liberia and Sierra Leone. General principles are outlined for trial designs intended to be deployed quickly, adapt flexibly and provide results soon enough to influence the course of the current epidemic rather than just providing evidence for use should Ebola break out again. Lessons are drawn for the conduct of clinical research in future outbreaks of infectious diseases, where the sequence of events may or may not be similar to the West African Ebola epidemic.
© The Author(s) 2016.

Entities:  

Keywords:  Ebola; infectious disease; multi-stage approach; sequential design; single-arm design; stopping rule

Mesh:

Substances:

Year:  2016        PMID: 26768556      PMCID: PMC5856305          DOI: 10.1177/1740774515617740

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  10 in total

1.  Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.

Authors:  John Whitehead; Tatsuru Matsushita
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

2.  Overrunning and underrunning in sequential clinical trials.

Authors:  J Whitehead
Journal:  Control Clin Trials       Date:  1992-04

3.  Bayesian sample size for exploratory clinical trials incorporating historical data.

Authors:  John Whitehead; Elsa Valdés-Márquez; Patrick Johnson; Gordon Graham
Journal:  Stat Med       Date:  2008-06-15       Impact factor: 2.373

4.  Designing phase II studies in the context of a programme of clinical research.

Authors:  J Whitehead
Journal:  Biometrics       Date:  1985-06       Impact factor: 2.571

5.  An exact method for analysis following a two-stage phase II cancer clinical trial.

Authors:  Gordana Jovic; John Whitehead
Journal:  Stat Med       Date:  2010-12-30       Impact factor: 2.373

6.  Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.

Authors:  Amy Cotterill; John Whitehead
Journal:  Stat Med       Date:  2015-01-26       Impact factor: 2.373

7.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

8.  Evaluating clinical trial designs for investigational treatments of Ebola virus disease.

Authors:  Ben S Cooper; Maciej F Boni; Wirichada Pan-ngum; Nicholas P J Day; Peter W Horby; Piero Olliaro; Trudie Lang; Nicholas J White; Lisa J White; John Whitehead
Journal:  PLoS Med       Date:  2015-04-14       Impact factor: 11.069

9.  Bayesian methods for the design and interpretation of clinical trials in very rare diseases.

Authors:  Lisa V Hampson; John Whitehead; Despina Eleftheriou; Paul Brogan
Journal:  Stat Med       Date:  2014-06-23       Impact factor: 2.373

10.  Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.

Authors:  Bruce Aylward; Philippe Barboza; Luke Bawo; Eric Bertherat; Pepe Bilivogui; Isobel Blake; Rick Brennan; Sylvie Briand; Jethro Magwati Chakauya; Kennedy Chitala; Roland M Conteh; Anne Cori; Alice Croisier; Jean-Marie Dangou; Boubacar Diallo; Christl A Donnelly; Christopher Dye; Tim Eckmanns; Neil M Ferguson; Pierre Formenty; Caroline Fuhrer; Keiji Fukuda; Tini Garske; Alex Gasasira; Stephen Gbanyan; Peter Graaff; Emmanuel Heleze; Amara Jambai; Thibaut Jombart; Francis Kasolo; Albert Mbule Kadiobo; Sakoba Keita; Daniel Kertesz; Moussa Koné; Chris Lane; Jered Markoff; Moses Massaquoi; Harriet Mills; John Mike Mulba; Emmanuel Musa; Joel Myhre; Abdusalam Nasidi; Eric Nilles; Pierre Nouvellet; Deo Nshimirimana; Isabelle Nuttall; Tolbert Nyenswah; Olushayo Olu; Scott Pendergast; William Perea; Jonathan Polonsky; Steven Riley; Olivier Ronveaux; Keita Sakoba; Ravi Santhana Gopala Krishnan; Mikiko Senga; Faisal Shuaib; Maria D Van Kerkhove; Rui Vaz; Niluka Wijekoon Kannangarage; Zabulon Yoti
Journal:  N Engl J Med       Date:  2014-09-22       Impact factor: 91.245

  10 in total
  11 in total

1.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

2.  Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.

Authors:  Susan S Ellenberg; Gerald T Keusch; Abdel G Babiker; Kathryn M Edwards; Roger J Lewis; Jens D Lundgren; Charles D Wells; Fred Wabwire-Mangen; Keith P W J McAdam
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

3.  The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael Proschan; Peter Jahrling; Lisa Hensley; Elizabeth Higgs; H Clifford Lane
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

4.  Improving readiness for recruitment through simulated trial activation: the Adjuvant Steroids in Adults with Pandemic influenza (ASAP) trial.

Authors:  Wei Shen Lim; Garry Meakin; Clare Brittain; Thomas Bewick; Lelia Duley
Journal:  Trials       Date:  2017-11-16       Impact factor: 2.279

5.  Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa.

Authors:  Sara Carazo Perez; Elin Folkesson; Xavier Anglaret; Abdoul-Habib Beavogui; Emmanuel Berbain; Alseny-Modet Camara; Evelyn Depoortere; Annabelle Lefevre; Piet Maes; Kristian Nødtvedt Malme; Jean-Marie Denis Malvy; Sien Ombelet; Geertrui Poelaert; Daouda Sissoko; Alexis Tounkara; Pierre Trbovic; Pascal Piguet; Annick Antierens
Journal:  PLoS Negl Trop Dis       Date:  2017-06-22

6.  Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.

Authors:  Milena Apetito Akamatsu; Vitor Anselmo Sakihara; Bianca Pereira Carvalho; Aline de Paiva Abrantes; Maria A Sakauchi Takano; Eduardo Alfredo Adami; Fernando Seiji Yonehara; Patrícia Dos Santos Carneiro; Stefanni Rico; Alessandra Schanoski; Maurício Meros; Adrian Simpson; Tony Phan; Christopher B Fox; Paulo Lee Ho
Journal:  PLoS One       Date:  2020-06-03       Impact factor: 3.240

Review 7.  The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research.

Authors:  Prossy Naluyima; Willy Kayondo; Chi Ritchie; Joseph Wandege; Sharon Kagabane; Lydia Tumubeere; Brenda Kusiima; Daniel Kibombo; Sharon Atukunda; Christine Nanteza; Harriet Nabirye; Francis Bunjo Mugabi; Sarah Namuyanja; Christopher Hatcher; Hypaitia Rauch; Moses Mukembo; Patrick Musinguzi; Nathan Sanders; Elizabeth Turesson; Christian Cando; Richard Walwema; Derrick Mimbe; Janice Hepburn; Danielle Clark; Mohammed Lamorde; Hannah Kibuuka; Saima Zaman; Anthony P Cardile; Karen A Martins
Journal:  PLoS Negl Trop Dis       Date:  2019-12-19

8.  Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak.

Authors:  Pauline Manchon; Drifa Belhadi; France Mentré; Cédric Laouénan
Journal:  BMC Med Res Methodol       Date:  2021-05-06       Impact factor: 4.615

9.  The Ebola clinical trials: a precedent for research ethics in disasters.

Authors:  Philippe Calain
Journal:  J Med Ethics       Date:  2016-08-29       Impact factor: 2.903

10.  Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease:  plasma concentrations exceed target levels, with drug accumulation in the most severe patients.

Authors:  Janet T Scott; Raman Sharma; Luke W Meredith; Jake Dunning; Catrin E Moore; Foday Sahr; Steve Ward; Ian Goodfellow; Peter Horby
Journal:  EBioMedicine       Date:  2020-01-14       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.